(Q40619528)

22 September 2017

title

Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma (English)

1 reference

22 September 2017

1 reference

1 reference

Robert A Parise

1

1 reference

22 September 2017

Ramesh K Ramanathan

series ordinal

2

1 reference

22 September 2017

William C Zamboni

series ordinal

3

1 reference

22 September 2017

Merrill J Egorin

series ordinal

4

1 reference

22 September 2017

publication date

1 January 2003

1 reference

Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences

22 September 2017

published in

1 reference

22 September 2017

volume

783

1 reference

22 September 2017

issue

1

1 reference

22 September 2017

page(s)

231-236

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

22 September 2017

1 reference

7 January 2021

The taxoids. Comparative clinical pharmacology and therapeutic potential

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience.

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

Paclitaxel (Taxol): a novel anticancer chemotherapeutic drug

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

Clinical pharmacokinetics of docetaxel.

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

A sensitive docetaxel assay in plasma by solid-phase extraction and high performance liquid chromatography-UV detection: validation and suitability in phase I clinical trial pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

Bio-analysis of docetaxel and hydroxylated metabolites in human plasma by high-performance liquid chromatography and automated solid-phase extraction

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

A rapid reversed phase high performance liquid chromatographic method for the determination of docetaxel (Taxotere) in human plasma using a column switching technique

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

Rapid and sensitive determination of paclitaxel in mouse plasma by high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

Assay of paclitaxel (Taxol) in plasma and urine by high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection.

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

Rapid and sensitive determination of paclitaxel (Taxol(R)) in environmental samples by high-performance liquid chromatography tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

Cellular uptake profile of paclitaxel using liquid chromatography tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

High-performance liquid chromatography tandem mass spectrometry procedure with automated solid phase extraction sample preparation for the quantitative determination of paclitaxel (Taxol) in human plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

Structural characterization of mono- and dihydroxylated metabolites of paclitaxel in rat bile using liquid chromatography/ion spray tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1016%2FS1570-0232%2802%2900659-1

7 January 2021

10.1016/S1570-0232(02)00659-1

Identifiers

DOI

1 reference

22 September 2017

1 reference